HDFC Mid Cap Fund Regular-Growth
The fund is rated 4.5 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Above-average fund size of Rs 105,142.69 crore was a minor drawback.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 105142.694 AUM and a 1.3 expense ratio. Considering all these factors, we have rated this fund as 4.5 star.
અમારો સ્કોર લાંબા ગાળાની કામગીરી, જોખમ અને સાતત્યને વજન આપે છે — ફક્ત ભૂતકાળના વળતરને નહીં.
રિટર્ન
25 Sep 2026 મુજબ
જોખમ ગુણોત્તર
31 Aug 2026 મુજબ
પોર્ટફોલિયો
31 Aug 2026 મુજબ
માર્કેટ-કેપ વિભાજન
સેક્ટર ફાળવણી
હોલ્ડિંગ્સ (80)
| હોલ્ડિંગ | ફંડનો % | મૂલ્ય | શેર |
|---|---|---|---|
| Others | 6.91% | ₹7,484.03 Cr | — |
| The Federal Bank Ltd. | 4.21% | ₹4,559.52 Cr | 12,78,25,000 |
| AU Small Finance Bank Ltd. | 3.98% | ₹4,316.27 Cr | 3,97,37,347 |
| Max Financial Services Ltd. | 3.79% | ₹4,108.03 Cr | 2,61,14,231 |
| Ipca Laboratories Ltd. | 3.30% | ₹3,575.69 Cr | 1,81,05,658 |
| Glenmark Pharmaceuticals Ltd. | 3.07% | ₹3,325.23 Cr | 1,34,08,183 |
| Indian Bank | 3.06% | ₹3,312.3 Cr | 3,68,54,482 |
| Balkrishna Industries Ltd. | 3.02% | ₹3,268.66 Cr | 1,43,41,251 |
| Coforge Ltd. | 2.86% | ₹3,101.16 Cr | 1,56,20,600 |
| Fortis Healthcare Ltd. | 2.69% | ₹2,911.32 Cr | 3,21,01,862 |
ફંડ વિગતો
to generate long-term capital appreciation / income. investment predominantly in Mid-Cap companies.
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies.
Exit load of 1% if redeemed within 1 year.